Progress of mechanisms of glucagon-like peptide-1 in ameliorating nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, insulin resistance, type 2 diabetes mellitus, and lipid disorders. With the growing incidence of obesity and diabetes, NAFLD has become the most common chronic liver disease worldwide. At present, the treatment of NAFLD is mainly limited to lifestyle intervention, reduction of weight, and use of lipid-lowering drugs, but there is no specific drug for NAFLD. Glucagon-like peptide-1 (GLP-1) has been approved for diabetes and obesity, and numerous clinical and preclinical studies have shown that GLP-1 could alleviate NAFLD by multiple mechanisms. In this paper, the mechanisms of GLP-1 in improving NAFLD are summarized as follows.